Search

Incyte Corp

Închisă

SectorSănătate

126.87 1.76

Rezumat

Modificarea prețului

24h

Curent

Minim

123.38

Maxim

127.63

Indicatori cheie

By Trading Economics

Venit

282M

586M

Vânzări

401M

1.7B

P/E

Medie Sector

15.899

55.725

EPS

2.8

Marjă de profit

34.982

Angajați

2,844

EBITDA

384M

752M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+4.93% upside

Dividende

By Acuity

Următoarele câștiguri

27 oct. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

1.5B

25B

Deschiderea anterioară

125.11

Închiderea anterioară

126.87

Sentimentul știrilor

By Acuity

50%

50%

119 / 339 Clasament în Healthcare

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 sept. 2026, 23:45 UTC

Incyte Corp is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

21 sept. 2026, 20:06 UTC

News

Incyte Corp's shares are declining despite announcing an expanded partnership with Specialised Therapeutics to commercialize ruxolitinib cream in Australia.

18 sept. 2026, 22:51 UTC

Incyte Corp is trading modestly higher in after-market hours, reflecting broader market trends amid mixed equity performance and rising treasury yields.

17 sept. 2026, 23:26 UTC

News

Incyte Corp's stock is trading higher in after-market hours as investors await an FDA decision on zilurgisertib, with a target date of September 26.

16 sept. 2026, 23:06 UTC

Incyte Corp is trading lower in after-market hours, marking its lowest point since the market closed and remaining below its 20-day moving average.

15 sept. 2026, 23:06 UTC

Incyte Corp shares are trading lower in after-market hours, reflecting broader market fluctuations and remaining below the 20-day moving average.

14 sept. 2026, 20:08 UTC

Incyte Corp's shares are higher amid overall market gains, despite earlier volatility. Broader market concerns include rising crude oil prices and inflation.

11 sept. 2026, 22:01 UTC

Incyte Corp shares are higher in after-market trading, despite a decline in consumer sentiment reflected by the Michigan Consumer Sentiment Index.

10 sept. 2026, 19:36 UTC

Event
News

Incyte's MINJUVI receives funding in Ontario for lymphoma treatment. Shares are lower despite this development, currently trading below their 20-day moving average.

9 sept. 2026, 19:07 UTC

Event
Social Media

Incyte Corp gains amid positive sentiment for its upcoming PDUFA date for Zilurgisertib, scheduled for September 26, despite earlier session volatility.

8 sept. 2026, 20:02 UTC

News

Incyte Corp shares are lower today, driven by a downturn in the Biotechnology sub-sector. Analysts maintain a consensus "Moderate Buy" rating on the stock.

4 sept. 2026, 23:55 UTC

Incyte Corp shares are higher in after-market hours, reaching an early peak before settling back. No specific news was identified to explain the movement.

3 sept. 2026, 19:16 UTC

Incyte Corp shares are lower amid broader market declines influenced by rising jobless claims. The stock remains above its 20-day moving average.

2 sept. 2026, 23:16 UTC

Incyte Corp shares are trading higher in after-market hours, amid a weaker-than-expected ADP payrolls report that may influence Federal Reserve interest rate decisions.

1 sept. 2026, 22:06 UTC

Incyte Corp shares are higher in after-market hours, though no specific news explains the movement. Broader market pressures persist from rising bond yields.

31 aug. 2026, 20:04 UTC

News

Incyte Corp shares are lower amid broader market weakness following comments from Warsh at the Jackson Hole Economic Symposium on inflation and monetary policy.

28 aug. 2026, 23:21 UTC

News

Incyte Corp shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down amid rising Treasury yields and mixed ESMO data sentiment.

27 aug. 2026, 20:07 UTC

News

Incyte Corp shares are lower today, reflecting broader market declines. Analysts from TD Cowen upgraded the stock to a strong buy amid ongoing positive sentiment.

26 aug. 2026, 19:36 UTC

Incyte Corp shares are lower during Wednesday's session, having reached a session low earlier. No specific news was identified to explain the price movement.

25 aug. 2026, 23:21 UTC

Incyte Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by a decline in crude oil prices and easing treasury yields.

24 aug. 2026, 23:01 UTC

Incyte Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

21 aug. 2026, 19:46 UTC

News

Incyte Corp's stock is higher today, supported by President Pablo J. Cagnoni's recent sale of 10,801 shares at $125.56. The stock remains near its one-month high.

20 aug. 2026, 23:41 UTC

Incyte Corp shares are higher in after-market trading, recovering from a slight dip and positioned above the 20-day moving average. No specific news was identified.

19 aug. 2026, 23:01 UTC

Incyte Corp shares declined in after-hours trading, pulling back from earlier gains. The stock remains above its 20-day moving average and near a one-month high.

17 aug. 2026, 20:06 UTC

News

Piper Sandler raised Incyte Corp's price target to $130 from $110, contributing to the stock's upward movement after four days of declines.

14 aug. 2026, 19:36 UTC

Incyte Corp shares are lower, continuing a recent decline amid concerns over July retail sales, which fell 0.6% against expectations for growth.

13 aug. 2026, 23:26 UTC

Incyte Corp shares are lower in after-market hours, despite broader market gains from reduced Federal Reserve rate hike expectations. No specific news was identified.

10 aug. 2026, 19:36 UTC

Incyte Corp shares are higher today, maintaining an upward trend since Friday. The stock remains above its 20-day moving average, reflecting solid performance.

6 aug. 2026, 19:44 UTC

Incyte Corp shares are lower amid broader biotechnology sector declines. The stock is trading near the lower end of its one-month range.

5 aug. 2026, 19:56 UTC

Incyte Corp shares are lower today, retracing from earlier session gains. No specific news was identified to explain the decline.

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

4.93% sus

Prognoză pe 12 luni

Medie 130.789 USD  4.93%

Maxim 155 USD

Minim 104 USD

În baza a 21 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

21 ratings

11

Cumpărare

10

Păstrare

0

Vânzare

Sentiment

By Acuity

119 / 339 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation